Kinase signaling pathways as targets for intervention in pancreatic cancer

Meir Preis, Murray Korc

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related mortality in the United States. The prognosis of patients with PDAC is extremely poor with a median survival of 6 months, in part due to the advanced stage at the time of diagnosis and early metastatic spread. A considerable body of evidence points to the involvement of the tyrosine kinase and serine/threonine kinase pathways as major effectors in pancreatic cancer development and as potential targets for intervention. These pathways regulate multiple cellular processes including cell growth, proliferation, migration, invasion and resistance to apoptosis. The relatively recent introduction of novel therapies targeting tyrosine kinase and serine/threonine kinase pathways have yielded dramatic results in certain hematological malignancies, and have resulted in significant advances in our ability to treat patients with melanoma, breast, lung and colon cancer, thereby leading to improved survival and quality of life. Unfortunately, similar therapeutic improvements have not occurred in PDAC. Thus, despite encouraging phase I/II studies, the vast majority of phase-III studies have failed to demonstrate improved efficacy in PDAC. This review will provide an overview on the different kinase signaling pathways in PDAC and the supporting data on targeted therapies available from pre-clinical and clinical studies.

Original languageEnglish (US)
Pages (from-to)752-761
Number of pages10
JournalCancer Biology and Therapy
Volume9
Issue number10
StatePublished - May 15 2010
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
Phosphotransferases
Protein-Serine-Threonine Kinases
Protein-Tyrosine Kinases
Survival
Hematologic Neoplasms
Colonic Neoplasms
Melanoma
Lung Neoplasms
Therapeutics
Quality of Life
Cell Proliferation
Apoptosis
Breast Neoplasms
Mortality
Neoplasms

Keywords

  • Kinase signaling
  • Pancreatic cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Kinase signaling pathways as targets for intervention in pancreatic cancer. / Preis, Meir; Korc, Murray.

In: Cancer Biology and Therapy, Vol. 9, No. 10, 15.05.2010, p. 752-761.

Research output: Contribution to journalArticle

Preis, Meir ; Korc, Murray. / Kinase signaling pathways as targets for intervention in pancreatic cancer. In: Cancer Biology and Therapy. 2010 ; Vol. 9, No. 10. pp. 752-761.
@article{c31c3c8e3c414f8ab60a95971af6cc77,
title = "Kinase signaling pathways as targets for intervention in pancreatic cancer",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related mortality in the United States. The prognosis of patients with PDAC is extremely poor with a median survival of 6 months, in part due to the advanced stage at the time of diagnosis and early metastatic spread. A considerable body of evidence points to the involvement of the tyrosine kinase and serine/threonine kinase pathways as major effectors in pancreatic cancer development and as potential targets for intervention. These pathways regulate multiple cellular processes including cell growth, proliferation, migration, invasion and resistance to apoptosis. The relatively recent introduction of novel therapies targeting tyrosine kinase and serine/threonine kinase pathways have yielded dramatic results in certain hematological malignancies, and have resulted in significant advances in our ability to treat patients with melanoma, breast, lung and colon cancer, thereby leading to improved survival and quality of life. Unfortunately, similar therapeutic improvements have not occurred in PDAC. Thus, despite encouraging phase I/II studies, the vast majority of phase-III studies have failed to demonstrate improved efficacy in PDAC. This review will provide an overview on the different kinase signaling pathways in PDAC and the supporting data on targeted therapies available from pre-clinical and clinical studies.",
keywords = "Kinase signaling, Pancreatic cancer, Targeted therapy",
author = "Meir Preis and Murray Korc",
year = "2010",
month = "5",
day = "15",
language = "English (US)",
volume = "9",
pages = "752--761",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "10",

}

TY - JOUR

T1 - Kinase signaling pathways as targets for intervention in pancreatic cancer

AU - Preis, Meir

AU - Korc, Murray

PY - 2010/5/15

Y1 - 2010/5/15

N2 - Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related mortality in the United States. The prognosis of patients with PDAC is extremely poor with a median survival of 6 months, in part due to the advanced stage at the time of diagnosis and early metastatic spread. A considerable body of evidence points to the involvement of the tyrosine kinase and serine/threonine kinase pathways as major effectors in pancreatic cancer development and as potential targets for intervention. These pathways regulate multiple cellular processes including cell growth, proliferation, migration, invasion and resistance to apoptosis. The relatively recent introduction of novel therapies targeting tyrosine kinase and serine/threonine kinase pathways have yielded dramatic results in certain hematological malignancies, and have resulted in significant advances in our ability to treat patients with melanoma, breast, lung and colon cancer, thereby leading to improved survival and quality of life. Unfortunately, similar therapeutic improvements have not occurred in PDAC. Thus, despite encouraging phase I/II studies, the vast majority of phase-III studies have failed to demonstrate improved efficacy in PDAC. This review will provide an overview on the different kinase signaling pathways in PDAC and the supporting data on targeted therapies available from pre-clinical and clinical studies.

AB - Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related mortality in the United States. The prognosis of patients with PDAC is extremely poor with a median survival of 6 months, in part due to the advanced stage at the time of diagnosis and early metastatic spread. A considerable body of evidence points to the involvement of the tyrosine kinase and serine/threonine kinase pathways as major effectors in pancreatic cancer development and as potential targets for intervention. These pathways regulate multiple cellular processes including cell growth, proliferation, migration, invasion and resistance to apoptosis. The relatively recent introduction of novel therapies targeting tyrosine kinase and serine/threonine kinase pathways have yielded dramatic results in certain hematological malignancies, and have resulted in significant advances in our ability to treat patients with melanoma, breast, lung and colon cancer, thereby leading to improved survival and quality of life. Unfortunately, similar therapeutic improvements have not occurred in PDAC. Thus, despite encouraging phase I/II studies, the vast majority of phase-III studies have failed to demonstrate improved efficacy in PDAC. This review will provide an overview on the different kinase signaling pathways in PDAC and the supporting data on targeted therapies available from pre-clinical and clinical studies.

KW - Kinase signaling

KW - Pancreatic cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77953705152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953705152&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77953705152

VL - 9

SP - 752

EP - 761

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 10

ER -